At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Dose Escalation Study of NK-92 Cell Infusions in Patients With Hematological Malignancies in Relapse After Autologous Stem Cell Transplantation.
In Brief
A Phase 1 clinical trial evaluating NK-92 cells for Leukemia and 3 related conditions. Completed, enrolled 8 participants across 1 site.
Detailed Summary
The purpose of this study is to find out how many irradiated natural killer (NK) cells can be safely given to patients with cancer that has recurred after an autologous stem cell transplant, and to see what effects (good and bad) it has on the patient and their cancer. This research is being done because currently, there is no cure or effective treatment for blood-borne cancers when it has come back after an autologous stem cell transplant.
Study Details
Timeline
Interventions
Cells are administered as an intravenous infusion over one hour on days 1, 3 and 5 of each cycle of treatment. Patients can receive up to 6 cycles, which are administered monthly. Cell dosage is as follows: * Level I: 1x10\^9 cells/m\^2 * Level II: 3x10\^9 cells/m\^2 * Level III: 5x10\^9 cells/m\^2